US-based clinical-stage biotechnology company RadioMedix has collaborated with AREVA Med to begin a Phase l trial of 212Pb-AR-RMX (AlphaMedix) to treat patients with somatostatin receptor positive neuroendocrine tumours (NETs).

The open-label, dose escalation study seeks to evaluate safety, bio-distribution, and preliminary effectiveness of AlphaMedixin adult patients with differentiated NETs.

AlphaMedix is a combination of a somatostatin (SST) analogue radiolabeled with 212Pb isotope that is used for targeted alpha-emitter therapy (TAT).

The trial is set to enrol patients at Excel Diagnostic and Nuclear Oncology Center in Houston, Texas, US.

“This has tremendous potential to treat patients with NET and overcome some of the limitations of current peptide receptor radionuclide therapy.”

RadioMedix chairman and CEO Dr Ebrahim Delpassand said: “Targeted alpha-emitter therapy (TAT) is the wave of the future in nuclear oncology and has a tremendous potential to treat patients with NET and overcome some of the limitations of current peptide receptor radionuclide therapy (PRRT).”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NETs are a mixed group of rare neoplasms that originate from neuroendocrine cells and occur primarily in the gastrointestinal tract and pancreas.

The situation can also occur in other tissues such as thymus, lung, and other uncommon sites including ovaries, heart, and prostate.

Most of the NETs strongly demonstrate somatostatin receptors (SSTRs).

In June last year, RadioMedix and AREVA Med concluded an exploratory clinical trial that examined the biodistribution and safety of 203Pb-AR-RMX in patients with somatostatin receptor positive NETs.